Skip to main content Accessibility help
×
Home

Oropharyngeal cancer: United Kingdom National Multidisciplinary Guidelines

  • H Mehanna (a1), M Evans (a2), M Beasley (a3), S Chatterjee (a4), M Dilkes (a5), J Homer (a6), J O'Hara (a7), M Robinson (a8), R Shaw (a9) and P Sloan (a10)...

Abstract

This is the official guideline endorsed by the specialty associations involved in the care of head and neck cancer patients in the UK. There has been significant debate in the management of oropharyngeal cancer in the last decade, especially in light of the increased incidence, clarity on the role of the human papilloma virus in this disease and the treatment responsiveness of the human papilloma virus positive cancers. This paper discusses the evidence base pertaining to the management of oropharyngeal cancer and provides recommendations on management for this group of patients receiving cancer care.

Recommendations

• Cross-sectional imaging is required in all cases to complete assessment and staging. (R)

• Magnetic resonance imaging is recommended for primary site and computed tomography scan for neck and chest. (R)

• Positron emission tomography combined with computed tomography scanning is recommended for the assessment of response after chemoradiotherapy, and has a role in assessing recurrence. (R)

• Examination under anaesthetic is strongly recommended, but not mandatory. (R)

• Histological diagnosis is mandatory in most cases, especially for patients receiving treatment with curative intent. (R)

• Oropharyngeal carcinoma histopathology reports should be prepared according to The Royal College of Pathologists Guidelines. (G)

• Human papilloma virus (HPV) testing should be carried out for all oropharyngeal squamous cell carcinomas as recommended in The Royal College of Pathologists Guidelines. (R)

• Human papilloma virus testing for oropharyngeal cancer should be performed within a diagnostic service where the laboratory procedures and reporting standards are quality assured. (G)

• Treatment options for T1–T2 N0 oropharyngeal squamous cell carcinoma include radical radiotherapy or transoral surgery and neck dissection (with post-operative (chemo)radiotherapy if there are adverse pathological features on histological examination). (R)

• Transoral surgery is preferable to open techniques and is associated with good functional outcomes in retrospective series. (R)

• If treated surgically, neck dissection should include levels II–IV and possibly level I. Level IIb can be omitted if there is no disease in level IIa. (R)

• If treated with radiotherapy, levels II–IV should be included, and possibly level Ib in selected cases. (R)

• Altering the modalities of treatment according to HPV status is currently controversial and should be undertaken only in clinical trials. (R)

• Where possible, patients should be offered the opportunity to enrol in clinical trials in the field. (G)

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Oropharyngeal cancer: United Kingdom National Multidisciplinary Guidelines
      Available formats
      ×

      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Oropharyngeal cancer: United Kingdom National Multidisciplinary Guidelines
      Available formats
      ×

      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Oropharyngeal cancer: United Kingdom National Multidisciplinary Guidelines
      Available formats
      ×

Copyright

This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.

Corresponding author

Address for correspondence: Prof Hisham Mehanna, Director, Institute of Head and Neck Studies and Education, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, Birmingham, UK E-mail: H.mehanna@bham.ac.uk

References

Hide All
1 Nasman, A, Attner, P, Hammarstedt, L, Du, J, Eriksson, M, Giraud, G, Ahrlund-Richter, S et al. Incidence of human papillomavirus (HPV) positive tonsillar carcinoma in Stockholm, Sweden: an epidemic of viral-induced carcinoma? Int J Cancer 2009;125:362–66
2 Mehanna, H, Beech, T, Nicholson, T, El-Hariry, I, McConkey, C, Paleri, V et al. Prevalence of human papillomavirus in oropharyngeal and nonoropharyngeal head and neck cancer – systematic review and meta-analysis of trends by time and region. Head Neck 2013;35:747–55
3 Lewis-Jones, H, Colley, S, Gibson, G. Imaging in head and neck cancer: United Kingdom National Multidisciplinary Guidelines. J Laryngol Otol 2016;130(Suppl S2):S28–31
4 Olliff, J, Richards, P, Connor, S, Wong, WL, Beale, T, Madani, G. Head and neck cancers. In: T, Nicholson, ed. Recommendations for Cross-Sectional Imaging in Cancer Management, 2nd edn. London: The Royal College of Radiologists, 2014. pp 319
5 Mehanna, H, Wong, WL, McConkey, CC, Rahman, J, Robinson, M, Hartley, A et al. PETCT Surveillance versus Neck Dissection in Advanced Head and Neck Cancer. N Engl J Med 2016;374:1444–54
6 Smeets, SJ, Hesselink, AT, Speel, EJ, Haesevoets, A, Snijders, PJ, Pawlita, M et al. A novel algorithm for reliable detection of human papillomavirus in paraffin embedded head and neck cancer specimen. Int J Cancer 2007;121:2465–72
7 Shaw, R, Robinson, M. The increasing clinical relevance of human papillomavirus type 16 (HPV-16) infection in oropharyngeal cancer. Br J Oral Maxillofac Surg 2011;49:423–29
8 Ang, KK, Harris, J, Wheeler, R, Weber, R, Rosenthal, DI, Nguyen-Tan, PF et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010;363:2435
9 Hafkamp, HC, Manni, JJ, Haesevoets, A, Voogd, AC, Schepers, M, Bot, FJ et al. Marked differences in survival rate between smokers and nonsmokers with HPV 16-associated tonsillar carcinomas. Int J Cancer 2008;122:2656–64
10 Gillison, ML, Zhang, Q, Jordan, R, Xiao, W, Westra, WH, Trotti, A et al. Tobacco smoking and increased risk of death and progression for patients with p16-positive and p16-negative oropharyngeal cancer. J Clin Oncol 2012;30:2102–111
11 Ward, MJ, Thirdborough, SM, Mellows, T, Riley, C, Harris, S, Suchak, K et al. Tumour-infiltrating lymphocytes predict for outcome in HPV-positive oropharyngeal cancer. Br J Cancer 2014;110:489500
12 Licitra, L, Perrone, F, Bossi, P, Suardi, S, Mariani, L, Artusi, R et al. High-risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma. J Clin Oncol 2006;24:5630–36
13 Haughey, BH, Hinni, ML, Salassa, JR, Hayden, RE, Grant, DG, Rich, JT et al. Transoral laser microsurgery as primary treatment for advanced-stage oropharyngeal cancer: a United States multicenter study. Head Neck 2011;33:1683–94
14 Fakhry, C, Westra, WH, Li, S, Cmelak, A, Ridge, JA, Pinto, H et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 2008;100:261–69
15 Cosmidis, A, Rame, JP, Dassonville, O, Temam, S, Massip, F, Poissonnet, G et al. T1-T2 NO oropharyngeal cancers treated with surgery alone. A GETTEC study. Eur Arch Otorhinolaryngol 2004;261:276–81
16 Mendenhall, WM, Morris, CG, Amdur, RJ, Hinerman, RW, Malyapa, RS, Werning, JW et al. Definitive radiotherapy for tonsillar squamous cell carcinoma. Am J Clin Oncol 2006;29:290–97
17 Moore, EJ, Hinni, ML. Critical review: transoral laser microsurgery and robotic-assisted surgery for oropharynx cancer including human papillomavirus-related cancer. Int J Radiat Oncol Biol Phys 2013;85:1163–67
18 Lim, YC, Koo, BS, Lee, JS, Lim, JY, Choi, EC. Distributions of cervical lymph node metastases in oropharyngeal carcinoma: therapeutic implications for the N0 neck. Laryngoscope 2006;116:1148–52
19 Furness, S, Glenny, AM, Worthington, HV, Pavitt, S, Oliver, R, Clarkson, JE et al. Interventions for the treatment of oral cavity and oropharyngeal cancer: chemotherapy. Cochrane Datab Syst Rev 2011:CD006386
20 O'Sullivan, B, Huang, SH, Siu, LL, Waldron, J, Zhao, H, Perez-Ordonez, B et al. Deintensification candidate subgroups in human papillomavirus-related oropharyngeal cancer according to minimal risk of distant metastasis. J Clin Oncol 2013;31:543–50
21 Gregoire, V, Ang, K, Budach, W, Grau, C, Hamoir, M, Langendijk, J et al. Delineation of the neck node levels for head and neck tumors: a 2013 update. DAHANCA, EORTC, HKNPCSG, NCIC CTG, NCRI, RTOG, TROG consensus guidelines. Radiother Oncol 2014;110:172181
22 Machtay, M, Moughan, J, Trotti, A, Garden, AS, Weber, RS, Cooper, JS et al. Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis. J Clin Oncol 2008;26:3582–89
23 Nutting, CM, Morden, JP, Harrington, KJ, Urbano, TG, Bhide, SA, Clark, C et al. Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial. Lancet Oncol 2011;12:127–36
24 Bernier, J, Cooper, JS, Pajak, TF, van Glabbeke, M, Bourhis, J, Forastiere, A et al. Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501). Head Neck 2005;27:843850
Type Description Title
PDF
Full supplement PDF

Full supplement PDF
Full supplement PDF

 PDF (10.5 MB)
10.5 MB

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed